Risk stratification based on prior fecal Hemoglobin (f-Hb) concentrations offers potential to enhance the effectiveness of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. This evidence concerns the gene GSTM1 and colorectal carcinoma.